Explore

Trendline Trendline
Charles River Laboratories Reports First-Quarter 2026 Results with Revenue Increase and Stock Repurchase

Charles River Laboratories Reports First-Quarter 2026 Results with Revenue Increase and Stock Repurchase

Charles River Laboratories Reports First-Quarter 2026 Results with Revenue Increase and Stock Repurchase
Trendline Trendline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Trendline Trendline
Pfizer Reports Strong First-Quarter Results and Reaffirms 2026 Guidance Amid Strategic Developments

Pfizer Reports Strong First-Quarter Results and Reaffirms 2026 Guidance Amid Strategic Developments

Pfizer Reports Strong First-Quarter Results and Reaffirms 2026 Guidance Amid Strategic Developments
Trendline Trendline
Novavax Surprises with Strong Q1 2026 Results, Stock Rises

Novavax Surprises with Strong Q1 2026 Results, Stock Rises

Novavax Surprises with Strong Q1 2026 Results, Stock Rises
Trendline Trendline
Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline

Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline

Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline
Trendline Trendline
EyePoint Pharmaceuticals Reports Q1 2026 Financial Results Amid Clinical Progress

EyePoint Pharmaceuticals Reports Q1 2026 Financial Results Amid Clinical Progress

EyePoint Pharmaceuticals Reports Q1 2026 Financial Results Amid Clinical Progress
Trendline Trendline
Novavax Exceeds Q1 2026 Expectations Despite Revenue Decline

Novavax Exceeds Q1 2026 Expectations Despite Revenue Decline

Novavax Exceeds Q1 2026 Expectations Despite Revenue Decline
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Trendline Trendline
Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Vertex Pharmaceuticals Reports Strong Q1 2026 Financial Results with 8% Revenue Growth

Vertex Pharmaceuticals Reports Strong Q1 2026 Financial Results with 8% Revenue Growth

Vertex Pharmaceuticals Reports Strong Q1 2026 Financial Results with 8% Revenue Growth